Clinical trial
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients…
NCT00422110 · UCB Pharma, Industry · Withdrawn
Key facts
| NCT number | NCT00422110 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures |
| Official title | A Phase IIb/III, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Seletracetam as Adjunctive Treatment in Subjects (≥16 to 70 Years Old) With Refractory Partial Onset Seizures. |
| Lead sponsor | UCB Pharma, Industry |
| Status | Withdrawn |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsies, Partial |
| Intervention type | Drug |
| Interventions | Seletracetam |
| Enrollment | 0 |
| Start date | May 1, 2008 |
| First posted | Jan 15, 2007 |
| Last update posted | May 28, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: